

Graduates

Continued.....



Continued.....

- In vivo proof of concept testing to confirm drug delivery, efficacy, and tolerance plus the next studies required to optimize compounds



Tolera plans to develop and commercialize therapies for the immune suppression modulation markets; to address unmet medical needs with safer, targeted solutions. These markets include segments such as oncology, autoimmune disease, and transplantation. Tolera owns an exclusive, worldwide license to a therapeutic monoclonal antibody for the transplantation and oncology markets. The antibody has been the subject of a number of pre-clinical, Phase I, and Phase II trials.

Other Kzoo Companies

Biosciences Research & Commercialization Center of Western Michigan University is located in SMIC and supports promising new life sciences ventures entering the commercialization phases of development in a number of ways:

- BioLaunch Pharmaceutical Development Services is a contract research group, which provides services that range from discovery research to early Phase II clinical
 - Startup and Gap Funding Assistance
 - The BRCC can help startups find additional venture capital funding through Southwest Michigan First, a Kalamazoo regional economic development organization
 - Facilities, Equipment, and Consulting
- The Write Phase** provides strategic medical writing for all phases of clinical development.

Kalsec provides spice extractives which function as natural flavors, natural colors, and natural antioxidants to the food and beverage industry worldwide.

(Continued...)

Other Kzoo Companies

Continued.....

Eurofins AVTech Laboratories utilizes state-of-the-art analytical technology to support clients' needs as they discover and develop new pharmaceutical candidates for approval by regulatory agencies. In-house techniques include HPLC utilizing both Fluorescence and UV Detection, Dissolution Testing, Immunoassays, Animal Health Product Testing, radioanalysis (sample oxidation and liquid scintillation analysis), GC, GC/MS, and LC/MS/MS.

MI High-Throughput Screening Center at M-TEC is a contract screening company offering maximally diverse 100,000 compound library, big pharma drug discovery and screening expertise, no license fees or royalties, and flexible screening platforms.

Jasper Clinical Research & Development is an independent phase I clinical pharmacology service provider specializing in innovative early clinical research studies.

MPI Research is a privately held Midwestern company that focuses on the nonclinical research needs of the pharmaceutical, biotech, chemical, agricultural, and related industries. MPI-CardIon, a division of MPI Research, is a specialized contract research unit that works with clients to investigate test compounds in vitro to evaluate their cardiac safety potential.

Bridge Organics is a research company engaged in the development of chemical processes for plant introduction as well as preparation of complex organic compounds including research compounds, metabolites, analytical impurities, analogs, stable isotope-labeled chemicals, and chemical library replacements or additions.

TEAM Pharmaceuticals is establishing a small scale GMP manufacturing facility in Kalamazoo.


Innovative Analytics provides high-value analytical and knowledge-building services for life science research.

BioMedPharmIS provides expert information retrieval and analysis services.

NanoMed is an early stage specialty pharmaceutical company dedicated to developing therapeutic and diagnostic products to treat or detect cancer and other serious diseases.

Borgess Medical Device Research Lab provides scientific collaboration in the basic research, design and preclinical development testing of novel cardiovascular devices in order to improve patient care.

southwest michigan
innovation center



Client Companies

Graduates

Other Kalamazoo
Companies

Client Companies



ADMETRx, Inc. strives to improve decision making in lead selection and lead optimization by providing high quality ADME profiling, data integration, analysis, and predictive modeling.



CeeTox, Inc. is a contract research organization that specializes in the in vitro assessment of toxicity of test compounds from Client organizations. CeeTox's proprietary predictive toxicology platform provides Clients with high-quality information in a timely and cost effective manner.



Emiliem's objective is to establish a pipeline of commercially attractive oncology drug products. The proprietary products are identified and developed both by an internal discovery function and through in-licensing and acquisition of pre-clinical and clinical development assets. The internal discovery function creates novel oncology therapeutics by identifying relevant, multiple kinase targets in cancer and designing multi-selectivity into each new lead compound.



Metabolic Solutions Development Company is developing innovative therapeutics to treat diabetes and related symptoms of metabolic syndrome. These therapeutic agents are PPAR γ -sparing insulin sensitizers that have improved profiles over the first generation thiazolidinedione class of insulin sensitizers. These agents may also have the potential to prevent progression of type 2 diabetes and to affect the progression of cardiovascular disease in non-diabetic patients.



Micromyx, LLC is a microbiology services company specializing in antibiotic research and development for the pharmaceutical and biotechnology industries. Primary capabilities include antimicrobial susceptibility testing, high throughput screening of compounds, and mechanism of action/resistance determinations of unique molecules.



NanoVir seeks small molecule antiviral therapies for the treatment of human papilloma virus (HPV) and cancer.



NephRx Corporation is developing two patent-protected peptides: 1) Wound Growth Factor (WGF) for the treatment of acute renal failure, 2) Antrum Mucosal Peptide (AMP-18) for treating oral mucositis and diseases of the GI tract.



ProNAi Therapeutics is a pre-clinical development-stage biopharmaceutical company focused on bringing to market novel Nucleic Acid inhibitor (NAi) drugs to treat complex genetic disease, initially in cancer. Its proprietary DNAi technology can selectively target known oncogenes as well as specific genes involved in other diseases. The overall impact is similar to that of antisense and RNAi products in development, but because it works at the level of DNA, ProNAi technology has significant advantages in terms of both efficacy and intellectual property protection.




With new industry emphasis on proteins as drugs and drug targets, there is a corresponding need for expression and production of these proteins and peptides at a high level of purity. Proteos, Inc. provides expertise in three areas of protein science: Custom Services in Protein Expression and Production, Protein Products, and Translational Research for Commercialization.



Single Source Procurement is a purchasing agency housed in SMIC. Through its extensive network and the negotiating expertise of the principals, SSP obtains superlative pricing for its clients. SSP staffs and stocks an on-site store room at SMIC from which resident companies may purchase laboratory supplies. SSP also coordinates ongoing routine procurement for companies as well as researching and negotiating one-time purchases. From lab supplies to equipment, from office supplies to furniture, Single Source Procurement can serve any client's need.



VENOMIX, INC. is developing the next generation of proprietary insecticide products. Based on spider peptides, these products are selected for having unique modes of action and are highly effective against insects and related pest species. The target markets have a combined value of \$15 billion and include agricultural, specialty non-crop, and animal health markets. VENOMIX products will be harmless to non-target species, including man, making them ideal products for the environmentally conscious 21st century.



zuSyn is a company focused on developing new anticancer drugs, specifically novel therapeutics that are derivatives of paclitaxel (Taxol) and related taxane diterpenoids. The company uses proprietary sugar attachment and modification methods to produce drug candidates with potentially better solubility and bioavailability profiles.

Graduates

AureoGen Biosciences, Inc. is developing a novel genetic-engineering technology that will propel the company into a leading position in the discovery and production of cyclic peptide-based drugs.



Kalexsyn, Inc. provides high-quality medicinal and synthetic chemistry services to life science customers. Kalexsyn is committed to partnering with their customers to achieve the best possible outcome for their projects.



PharmOptima, LLC provides consulting and laboratory services. As experts at drug discovery, PharmOptima helps clients create data packages, to maximize the value of their intellectual property.

The company's expertise includes:

- In vivo ADME; establishing bioanalytical assays using HPLC/MS-MS and other methods, pharmacokinetic studies, PK/PD analyses, brain uptake, ocular PK, and GLP sample analysis
- In vitro ADME including microsomal and cellular metabolic profiling, isozyme characterization, p450 inhibition, and protein binding

(Continued on next page...)